The cannabis pharmaceuticals market size has grown exponentially in recent years. It will grow from $9.43 billion in 2025 to $14.74 billion in 2026 at a compound annual growth rate (CAGR) of 56.3%. The growth in the historic period can be attributed to increasing recognition of therapeutic benefits of cannabinoids, expansion of medical cannabis prescriptions, availability of early cannabis-based drugs, growth of hospital-based pain management programs, regulatory approvals for select cannabis pharmaceuticals.
The cannabis pharmaceuticals market size is expected to see exponential growth in the next few years. It will grow to $85.68 billion in 2030 at a compound annual growth rate (CAGR) of 55.3%. The growth in the forecast period can be attributed to increasing investments in cannabis drug clinical trials, rising demand for standardized cannabinoid formulations, expansion of neurological and oncology applications, growing adoption of cannabis pharmaceuticals in hospitals, increasing regulatory harmonization across markets. Major trends in the forecast period include increasing development of prescription-grade cannabis medications, rising focus on clinical validation and trials, growing use in neurological and pain disorders, expansion of regulated pharmaceutical pipelines, enhanced emphasis on dosage precision.
The increasing prevalence of epilepsy is expected to drive the growth of the cannabis pharmaceuticals market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. The rise in epilepsy cases can be linked to improved diagnosis, heightened awareness, and more accurate reporting, as well as potential environmental, genetic, and lifestyle factors. Cannabis pharmaceuticals have demonstrated potential in managing epilepsy by using cannabinoids such as CBD to decrease the frequency and severity of seizures in patients who do not respond effectively to conventional anti-epileptic medications. For example, in February 2024, the World Health Organization, a Switzerland-based global health agency, reported that the number of people living with epilepsy worldwide had reached approximately 50 million. Consequently, the rising incidence of epilepsy is contributing to the expansion of the cannabis pharmaceuticals market.
Key players in the cannabis pharmaceuticals market are concentrating on developing innovative products, including advanced medical cannabis formulations, to address various medical conditions and enhance patient outcomes. Advanced medical cannabis formulations are specially designed cannabis-based products optimized for therapeutic use, containing precise doses of cannabinoids such as THC and CBD. For instance, in April 2024, Canexis Pharma AG, a Switzerland-based pharmaceutical company, obtained manufacturing and narcotics licenses from Swissmedic for cannabis pharmaceuticals. These approvals enable the company to produce high-quality medicinal active ingredients derived from CBD and THC. This development positions Canexis to meet the increasing demand for medical cannabis both within Switzerland and internationally. By securing these licenses, the company showcases its adherence to strict regulatory standards, bolstering its credibility and capacity to contribute to the rapidly evolving medical cannabis market.
In September 2025, High Tide, a Canada-based cannabis and wellness company, acquired a majority stake in Remexian Pharma GmbH for an undisclosed amount. Through this acquisition, High Tide aims to broaden its pharmaceutical and wellness portfolio, improve its product development capabilities, strengthen its presence in the European market, and drive long-term growth and strategic synergies. Remexian Pharma GmbH is a Germany-based pharmaceutical company focused on the development and production of innovative healthcare solutions.
Major companies operating in the cannabis pharmaceuticals market are Tilray Inc., Canopy Growth Corporation, Aurora Cannabis Inc., Aphria Inc., Cronos Group, GW Pharmaceuticals plc, Jazz Pharmaceuticals plc, Organigram Holdings Inc., Aleafia Health Inc., Avicanna Inc., Enveric Biosciences Inc., Auxly Cannabis Group Inc., Emerald Health Therapeutics Inc., Medical Marijuana Inc., Valens Company Inc., Curaleaf Holdings Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc.
North America was the largest region in the cannabis pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cannabis pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cannabis pharmaceuticals market by increasing costs of imported APIs, synthesis equipment, clinical trial materials, and pharmaceutical manufacturing technologies. North America and Europe are most affected due to reliance on global supply chains for drug development inputs, while Asia-Pacific faces higher export compliance costs. These tariffs are contributing to increased drug development expenses and longer commercialization timelines. However, they are also encouraging domestic pharmaceutical manufacturing, localized R&D investment, and regional production of cannabis-based prescription medicines.
The cannabis pharmaceuticals market research report is one of a series of new reports that provides cannabis pharmaceuticals market statistics, including cannabis pharmaceuticals industry global market size, regional shares, competitors with a cannabis pharmaceuticals market share, detailed cannabis pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the cannabis pharmaceuticals industry. This cannabis pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cannabis pharmaceuticals are prescription medications derived from cannabis compounds, developed to treat specific health conditions and manufactured under stringent clinical and regulatory guidelines. These medications harness the therapeutic properties of cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD), to manage conditions such as chronic pain, epilepsy, and multiple sclerosis.
The primary categories in cannabis pharmaceuticals include cannabinoid-based drugs, cannabis extracts, and synthetic cannabinoids. Cannabinoid-based drugs contain natural or synthetic cannabinoids, such as THC and CBD, to target various medical conditions. Formulation types include capsules and tablets, oils and tinctures, and topical solutions, which are applied in therapeutic areas such as cancer, neurological disorders, and pain management. Distribution occurs through hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals and clinics, rehabilitation centers, and research organizations.
The cannabis pharmaceuticals market consists of sales of dronabinol (synthetic THC) and cannabidiol (CBD) oil used to treat various medical conditions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cannabis pharmaceuticals market size is expected to see exponential growth in the next few years. It will grow to $85.68 billion in 2030 at a compound annual growth rate (CAGR) of 55.3%. The growth in the forecast period can be attributed to increasing investments in cannabis drug clinical trials, rising demand for standardized cannabinoid formulations, expansion of neurological and oncology applications, growing adoption of cannabis pharmaceuticals in hospitals, increasing regulatory harmonization across markets. Major trends in the forecast period include increasing development of prescription-grade cannabis medications, rising focus on clinical validation and trials, growing use in neurological and pain disorders, expansion of regulated pharmaceutical pipelines, enhanced emphasis on dosage precision.
The increasing prevalence of epilepsy is expected to drive the growth of the cannabis pharmaceuticals market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures resulting from abnormal electrical activity in the brain. The rise in epilepsy cases can be linked to improved diagnosis, heightened awareness, and more accurate reporting, as well as potential environmental, genetic, and lifestyle factors. Cannabis pharmaceuticals have demonstrated potential in managing epilepsy by using cannabinoids such as CBD to decrease the frequency and severity of seizures in patients who do not respond effectively to conventional anti-epileptic medications. For example, in February 2024, the World Health Organization, a Switzerland-based global health agency, reported that the number of people living with epilepsy worldwide had reached approximately 50 million. Consequently, the rising incidence of epilepsy is contributing to the expansion of the cannabis pharmaceuticals market.
Key players in the cannabis pharmaceuticals market are concentrating on developing innovative products, including advanced medical cannabis formulations, to address various medical conditions and enhance patient outcomes. Advanced medical cannabis formulations are specially designed cannabis-based products optimized for therapeutic use, containing precise doses of cannabinoids such as THC and CBD. For instance, in April 2024, Canexis Pharma AG, a Switzerland-based pharmaceutical company, obtained manufacturing and narcotics licenses from Swissmedic for cannabis pharmaceuticals. These approvals enable the company to produce high-quality medicinal active ingredients derived from CBD and THC. This development positions Canexis to meet the increasing demand for medical cannabis both within Switzerland and internationally. By securing these licenses, the company showcases its adherence to strict regulatory standards, bolstering its credibility and capacity to contribute to the rapidly evolving medical cannabis market.
In September 2025, High Tide, a Canada-based cannabis and wellness company, acquired a majority stake in Remexian Pharma GmbH for an undisclosed amount. Through this acquisition, High Tide aims to broaden its pharmaceutical and wellness portfolio, improve its product development capabilities, strengthen its presence in the European market, and drive long-term growth and strategic synergies. Remexian Pharma GmbH is a Germany-based pharmaceutical company focused on the development and production of innovative healthcare solutions.
Major companies operating in the cannabis pharmaceuticals market are Tilray Inc., Canopy Growth Corporation, Aurora Cannabis Inc., Aphria Inc., Cronos Group, GW Pharmaceuticals plc, Jazz Pharmaceuticals plc, Organigram Holdings Inc., Aleafia Health Inc., Avicanna Inc., Enveric Biosciences Inc., Auxly Cannabis Group Inc., Emerald Health Therapeutics Inc., Medical Marijuana Inc., Valens Company Inc., Curaleaf Holdings Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc.
North America was the largest region in the cannabis pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cannabis pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the cannabis pharmaceuticals market by increasing costs of imported APIs, synthesis equipment, clinical trial materials, and pharmaceutical manufacturing technologies. North America and Europe are most affected due to reliance on global supply chains for drug development inputs, while Asia-Pacific faces higher export compliance costs. These tariffs are contributing to increased drug development expenses and longer commercialization timelines. However, they are also encouraging domestic pharmaceutical manufacturing, localized R&D investment, and regional production of cannabis-based prescription medicines.
The cannabis pharmaceuticals market research report is one of a series of new reports that provides cannabis pharmaceuticals market statistics, including cannabis pharmaceuticals industry global market size, regional shares, competitors with a cannabis pharmaceuticals market share, detailed cannabis pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the cannabis pharmaceuticals industry. This cannabis pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cannabis pharmaceuticals are prescription medications derived from cannabis compounds, developed to treat specific health conditions and manufactured under stringent clinical and regulatory guidelines. These medications harness the therapeutic properties of cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD), to manage conditions such as chronic pain, epilepsy, and multiple sclerosis.
The primary categories in cannabis pharmaceuticals include cannabinoid-based drugs, cannabis extracts, and synthetic cannabinoids. Cannabinoid-based drugs contain natural or synthetic cannabinoids, such as THC and CBD, to target various medical conditions. Formulation types include capsules and tablets, oils and tinctures, and topical solutions, which are applied in therapeutic areas such as cancer, neurological disorders, and pain management. Distribution occurs through hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals and clinics, rehabilitation centers, and research organizations.
The cannabis pharmaceuticals market consists of sales of dronabinol (synthetic THC) and cannabidiol (CBD) oil used to treat various medical conditions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cannabis Pharmaceuticals Market Characteristics
3. Cannabis Pharmaceuticals Market Supply Chain Analysis
4. Global Cannabis Pharmaceuticals Market Trends and Strategies
5. Cannabis Pharmaceuticals Market Analysis of End Use Industries
7. Global Cannabis Pharmaceuticals Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cannabis Pharmaceuticals Total Addressable Market (TAM) Analysis for the Market
9. Cannabis Pharmaceuticals Market Segmentation
10. Cannabis Pharmaceuticals Market Regional and Country Analysis
11. Asia-Pacific Cannabis Pharmaceuticals Market
12. China Cannabis Pharmaceuticals Market
13. India Cannabis Pharmaceuticals Market
14. Japan Cannabis Pharmaceuticals Market
15. Australia Cannabis Pharmaceuticals Market
16. Indonesia Cannabis Pharmaceuticals Market
17. South Korea Cannabis Pharmaceuticals Market
18. Taiwan Cannabis Pharmaceuticals Market
19. South East Asia Cannabis Pharmaceuticals Market
20. Western Europe Cannabis Pharmaceuticals Market
21. UK Cannabis Pharmaceuticals Market
22. Germany Cannabis Pharmaceuticals Market
23. France Cannabis Pharmaceuticals Market
24. Italy Cannabis Pharmaceuticals Market
25. Spain Cannabis Pharmaceuticals Market
26. Eastern Europe Cannabis Pharmaceuticals Market
27. Russia Cannabis Pharmaceuticals Market
28. North America Cannabis Pharmaceuticals Market
29. USA Cannabis Pharmaceuticals Market
30. Canada Cannabis Pharmaceuticals Market
31. South America Cannabis Pharmaceuticals Market
32. Brazil Cannabis Pharmaceuticals Market
33. Middle East Cannabis Pharmaceuticals Market
34. Africa Cannabis Pharmaceuticals Market
36. Cannabis Pharmaceuticals Market Competitive Landscape and Company Profiles
37. Cannabis Pharmaceuticals Market Other Major and Innovative Companies
40. Cannabis Pharmaceuticals Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cannabis Pharmaceuticals Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cannabis pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cannabis pharmaceuticals? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cannabis pharmaceuticals market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Cannabinoid-Based Pharmaceuticals; Synthetic Cannabinoids2) By Therapeutic Application: Cancer; Neurological Disorders; Pain Management
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies; Government-Authorized Medical Cannabis Dispensaries
Subsegments:
1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals; CBD-Based Pharmaceuticals; Combination of THC and CBD Pharmaceuticals; Other Cannabinoid-Based Formulations2) By Synthetic Cannabinoids: Synthetic THC Analogues; Synthetic CBD Analogues; Synthetic Cannabinoid Receptor Agonists
Companies Mentioned: Tilray Inc.; Canopy Growth Corporation; Aurora Cannabis Inc.; Aphria Inc.; Cronos Group; GW Pharmaceuticals plc; Jazz Pharmaceuticals plc; Organigram Holdings Inc.; Aleafia Health Inc.; Avicanna Inc.; Enveric Biosciences Inc.; Auxly Cannabis Group Inc.; Emerald Health Therapeutics Inc.; Medical Marijuana Inc.; Valens Company Inc.; Curaleaf Holdings Inc.; Trulieve Cannabis Corp.; Green Thumb Industries Inc.; Cresco Labs Inc.; Columbia Care Inc.; Acreage Holdings Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cannabis Pharmaceuticals market report include:- Tilray Inc.
- Canopy Growth Corporation
- Aurora Cannabis Inc.
- Aphria Inc.
- Cronos Group
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals plc
- Organigram Holdings Inc.
- Aleafia Health Inc.
- Avicanna Inc.
- Enveric Biosciences Inc.
- Auxly Cannabis Group Inc.
- Emerald Health Therapeutics Inc.
- Medical Marijuana Inc.
- Valens Company Inc.
- Curaleaf Holdings Inc.
- Trulieve Cannabis Corp.
- Green Thumb Industries Inc.
- Cresco Labs Inc.
- Columbia Care Inc.
- Acreage Holdings Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 14.74 Billion |
| Forecasted Market Value ( USD | $ 85.68 Billion |
| Compound Annual Growth Rate | 55.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
